Skip to main content
Premium Trial:

Request an Annual Quote

HDC Board Member Forms Prognostic Test Startup

NEW YORK (GenomeWeb News) – Health Discovery Corp. said today that Richard Caruso, one of the firm’s board members, has resigned his position to form a new firm that intends to develop a breast cancer prognostic test based on HDC’s support vector machine technology.
Caruso, who will become a senior advisor to HDC, said in a statement that he will negotiate a license and development agreement with HDC to apply the technology to breast cancer applications. The new firm, called Smart Personalized Medicine, also intends to collaborate with MD Anderson Cancer Center on the test.
HDC will receive and undisclosed equity position in the startup as well as royalties paid on a per-test basis.
Stephen Barnhill, chairman and CEO of HDC, said that developing a prognostic test for breast cancer “requires focused attention and potentially millions of dollars in funding to succeed.” He added that since the focus of HDC has been on launching its prostate cancer test, providing rights to the breast cancer test to Smart Personalized Medicine provides “the best opportunity to achieve success for our shareholders.”

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.